Custom Synthesis outperforms; API underperforms

Company
05 Aug 2024
5 Min read 
  • Divis Laboratories 1QFY25 results update
  •  Financials and valuation overview
  •  Operating leverage outweighs product mix impact on YoY basis
  •  Highlights from the management commentary
  •  CS outlook robust; API outlook to improve gradually
  •  Reiterate Neutral stance on the stock
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities